Skip directly to content

Publications 1997

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

tagline 1997

New Drug Dilemmas
Scientific and Regulatory Issues in the Era of Antiretrovirai Polytherapy and a Viral Load-Driven Standard of Care
A Report to the FDA Antiviral Drugs Advisory Committee
14 July 1997 - Two comparisons seem to come inevitably to the minds of writers when they survey the past two years of AIDS research, with the enormous advances that have been made in the theory and practice of AIDS therapy: the first is the miraculous recovery of the biblical Lazarus, and the second is Alice in Wonderland, desperately trying to make sense of a world in which everything changes by the minute. These conflicting metaphors might also describe the position of advocates for people with HIV, trying to determine how patients can get maximal benefit from new drugs and new data, without entirely giving up our ability to continue to get more information about the optimal use of therapies.

It's Time to Change the Standard of Care For People With AIDS
24 February 1997 - ACTG 320 Proves that Indinavir and 3TC, when Added to AZT, Reduce AIDS and Death by Half when Compared with AZT and 3TC without Indinavir in HIV-Positive Individuals with Fewer than 200 CD4 Cells and Over Three Months of AZT Experience.

AIDS Activists Say New HIV Treatment Guidelines Could Revolutionize HIV Care for People With AIDS
Maximal HIV Suppression becomes the Goal of Antiretroviral Therapy -- Unequal Access to Care Still Hinders Treatment Advances
Members of the Treatment Action Group (TAG), a non-profit AIDS research and treatment advocacy group in New York City, offered strong praise for new guidelines on AIDS therapy announced today in the Federal Register. The new guidelines, developed by a consensus panel of researchers, clinicians and AIDS advocates for the U.S. Public Health Service (PHS), offer instructions for using powerful drugs, known as protease inhibitors, and new tests of HIV levels in the blood to monitor and treat HIV-infected patients.